BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/30/2019 3:02:03 AM | Browse: 965 | Download: 1162
 |
Received |
|
2019-03-17 07:41 |
|
Peer-Review Started |
|
2019-03-18 00:09 |
|
To Make the First Decision |
|
2019-04-17 05:29 |
|
Return for Revision |
|
2019-04-17 09:22 |
|
Revised |
|
2019-04-21 04:34 |
|
Second Decision |
|
2019-04-22 10:33 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-04-23 04:24 |
|
Articles in Press |
|
2019-04-23 04:24 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2019-04-25 22:09 |
|
Typeset the Manuscript |
|
2019-04-29 07:01 |
|
Publish the Manuscript Online |
|
2019-04-30 03:02 |
| ISSN |
2308-3840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Minireviews |
| Article Title |
Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and P-gp efflux pump
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Naina Mohamed Pakkir Maideen |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Naina Mohamed Pakkir Maideen, PhD, Doctor, Doctor, Pharmacist, Department of Pharmacy, Dubai Health Authority, Al Maktoum Bridge Street, Dubai 4545, United Arab Emirates. nmmaideen@dha.gov.ae |
| Key Words |
Drug interactions; Sitagliptin; Saxagliptin; Linagliptin; Gemigliptin; Teneligliptin; Vildagliptin; Anagliptin; CYP3A4; P-gp efflux pump |
| Core Tip |
The probability of adverse drug interactions is higher among Diabetic patients due to the concomitant administration of antidiabetic drugs with multiple medications to treat comorbidities such as hypertension, dyslipidemia, other cardiovascular problems, infections, depression, and others. Dipeptidyl peptidase 4 (DPP4) inhibitors are oral antidiabetic drugs approved to manage type 2 diabetes mellitus. Some of the DPP4 inhibitors have been identified as the substrates of CYP3A4/5 enzymes and P-gp efflux pump. The drugs inhibiting or inducing CYP3A4/5 enzymes and/or P-gp can alter the pharmacokinetics of DPP4 inhibitors. The prescribers and the pharmacists are required to be aware of the drugs altering the pharmacokinetics of DPP4 inhibitors significantly, to prevent adverse drug interactions. |
| Publish Date |
2019-04-30 03:02 |
| Citation |
Maideen NMP. Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and P-gp efflux pump. World J Meta-Anal 2019; 7(4): 156-161 |
| URL |
https://www.wjgnet.com/2308-3840/full/v7/i4/156.htm |
| DOI |
https://dx.doi.org/10.13105/wjma.v7.i4.156 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
